The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Expression of Cyclic GMP‐AMP Synthase in Patients With Systemic Lupus Erythematosus
Open accessAbstract
Objective: Type I interferon (IFN) is implicated in the pathogenesis of systemic lupus erythematosus (SLE) and interferonopathies such as Aicardi‐Goutières syndrome. A recently discovered DNA‐activated type I IFN pathway, cyclic GMP‐AMP synthase (cGAS), has been linked to Aicardi‐Goutières syndrome and mouse models of lupus. The aim of this study was to determine whether the cGAS pathway contributes to type I IFN production in patients with SLE. Methods: SLE disease activity was measured by the Safety of Estrogens in Lupus Erythematosus National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index. Expression of messenger RNA for cGAS and IFN‐stimulated genes (ISGs) was determined by quantitative polymerase chain reaction analysis. Cyclic GMP‐AMP (cGAMP) levels were examined by multiple reaction monitoring with ultra‐performance liquid chromatography tandem mass spectrometry. Results: Expression of cGAS in peripheral blood mononuclear cells (PBMCs) was significantly higher in SLE patients than in normal controls (n = 51 and n = 20 respectively; P < 0.01). There was a positive correlation between cGAS expression and the IFN score (P < 0.001). The expression of cGAS in PBMCs showed a dose response to type I IFN stimulation in vitro, consistent with it being an ISG. Targeted measurement of cGAMP by tandem mass spectrometry detected cGAMP in 15% of the SLE patients (7 of 48) but none of the normal (0 of 19) or rheumatoid arthritis (0 of 22) controls. Disease activity was higher in SLE patients with cGAMP versus those without cGAMP. Conclusion: Increased cGAS expression and cGAMP in a proportion of SLE patients indicates that the cGAS pathway should be considered as a contributor to type I IFN production. Whereas higher cGAS expression may be a consequence of exposure to type I IFN, detection of cGAMP in patients with increased disease activity indicates potential involvement of this pathway in disease expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lee-Kirsch, M. A., Gong, M., Chowdhury, D., Senenko, L., Engel, K., Lee, Y.-A., de Silva, U., Bailey, S. L., Witte, T., Vyse, T. J., et al. (2007) · Nature Genetics · doi:10.1038/ng2091 · Cited by 730 · cited 1×
“It is relevant to point out that 1– 2% of SLE patients have mutations in TREX1 which are thought to contribute to the lupuslike syndrome (35, 36).”
BackgroundGall, A., Treuting, P., Elkon, K. B., Loo, Y.-M., Gale, M., Barber, G. N., & Stetson, D. B. (2012) · Immunity · doi:10.1016/j.immuni.2011.11.018 · Cited by 510
Self-citation
Cited by
The cGAS–STING pathway as a therapeutic target in inflammatory diseases
Decout, A., Katz, J. D., Venkatraman, S., & Ablasser, A. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00524-z · Cited by 2,309
Molecular mechanisms and cellular functions of cGAS–STING signalling
Hopfner, K.-P., & Hornung, V. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0244-x · Cited by 2,052
Targeting STING with covalent small-molecule inhibitors
Haag, S. M., Gulen, M. F., Reymond, L., Gibelin, A., Abrami, L., Decout, A., Heymann, M., van der Goot, F. G., Turcatti, G., Behrendt, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0287-8 · Cited by 1,178
cGAS in action: Expanding roles in immunity and inflammation
Ablasser, A., & Chen, Z. J. (2019) · Science · doi:10.1126/science.aat8657 · Cited by 1,077
Structures and Mechanisms in the cGAS-STING Innate Immunity Pathway
Zhang, X., Bai, X.-C., & Chen, Z. J. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.013 · Cited by 827
Cellular functions of cGAS-STING signaling
Chen, C., & Xu, P. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2022.11.001 · Cited by 451
Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets
Crow, M. K. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-223741 · Cited by 398
Regulating IRFs in IFN Driven Disease
Jefferies, C. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00325 · Cited by 365
Nuclear hnRNPA2B1 initiates and amplifies the innate immune response to DNA viruses
Wang, L., Wen, M., & Cao, X. (2019) · Science · doi:10.1126/science.aav0758 · Cited by 348
Role of the cGAS–STING pathway in systemic and organ-specific diseases
Skopelja-Gardner, S., An, J., & Elkon, K. B. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00589-6 · Cited by 307
Self-citationKato, Y., Park, J., Takamatsu, H., Konaka, H., Aoki, W., Aburaya, S., Ueda, M., Nishide, M., Koyama, S., Hayama, Y., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-212988 · Cited by 304
Type I Interferons in Autoimmune Disease
Crow, M. K., Olferiev, M., & Kirou, K. A. (2019) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043952 · Cited by 291
Research Advances in How the cGAS-STING Pathway Controls the Cellular Inflammatory Response
Wan, D., Jiang, W., & Hao, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00615 · Cited by 270
Cytosolic DNA sensing by cGAS: regulation, function, and human diseases
Yu, L., & Liu, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00554-y · Cited by 269
Chandler, L., Yusuf, I., McClements, M., Barnard, A., MacLaren, R., & Xue, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144972 · Cited by 49
Reappraisal of Antimalarials in Interferonopathies: New Perspectives for Old Drugs
Piscianz, E., Cuzzoni, E., Sharma, R., Tesser, A., Sapra, P., & Tommasini, A. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666170911162331 · Cited by 15
Metadata
- Authors
- An, J., Durcan, L., Karr, R. M., Briggs, T. A., Rice, G. I., Teal, T. H., Woodward, J. J., & Elkon, K. B.
- Venue
- Arthritis & Rheumatology
- Publisher
- Wiley
- Published
- 2017-03-07
- Volume
- 69
- Issue
- 4
- Pages
- 800-807
- ISSN
- 2326-5191 (ISSN-L)
- 2326-5205
- OpenAlex
- W2601660331
- Cited by
- 198
- References
- 2
- FWCI
- 10.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.